Sunmax Biotechnology Co Ltd Asset Resilience Ratio

Latest as of September 2025: 10.53%

Sunmax Biotechnology Co Ltd asset resilience ratio. Sunmax Biotechnology Co Ltd (4728) has an Asset Resilience Ratio of 10.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4728 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$200.00 Million
≈ $6.30 Million USD Cash + Short-term Investments

Total Assets

NT$1.90 Billion
≈ $59.82 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio of Sunmax Biotechnology Co Ltd (2016–2024)

Asset resilience ratio of Sunmax Biotechnology Co Ltd from 2016 to 2024. This chart shows how Sunmax Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read 4728 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Sunmax Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sunmax Biotechnology Co Ltd (4728) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$200.00 Million 10.53%
Total Liquid Assets NT$200.00 Million 10.53%

Asset Resilience Insights

  • Moderate Liquidity: Sunmax Biotechnology Co Ltd has 10.53% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Sunmax Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Sunmax Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Sk Biopharmaceuticals Co Ltd
KO:326030
Biotechnology 0.14%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Ideaya Biosciences Inc
NASDAQ:IDYA
Biotechnology 47.46%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 3.03%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.12%
Hyundai Bioscience Co. Ltd
KQ:048410
Biotechnology 18.85%
DNA Link Inc
KQ:127120
Biotechnology 0.00%

Sunmax Biotechnology Co Ltd Asset Resilience Ratio by Year (2016–2024)

Sunmax Biotechnology Co Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Sunmax Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.86% NT$90.00 Million
≈ $2.84 Million
NT$1.85 Billion
≈ $58.31 Million
-0.10pp
2023-12-31 4.96% NT$107.10 Million
≈ $3.37 Million
NT$2.16 Billion
≈ $68.02 Million
-7.72pp
2022-12-31 12.68% NT$227.37 Million
≈ $7.16 Million
NT$1.79 Billion
≈ $56.50 Million
+7.50pp
2021-12-31 5.17% NT$76.79 Million
≈ $2.42 Million
NT$1.48 Billion
≈ $46.75 Million
-4.43pp
2020-12-31 9.60% NT$131.01 Million
≈ $4.13 Million
NT$1.36 Billion
≈ $42.98 Million
-3.38pp
2019-12-31 12.98% NT$144.42 Million
≈ $4.55 Million
NT$1.11 Billion
≈ $35.05 Million
-14.99pp
2018-12-31 27.97% NT$211.95 Million
≈ $6.68 Million
NT$757.89 Million
≈ $23.88 Million
+8.08pp
2017-12-31 19.88% NT$131.40 Million
≈ $4.14 Million
NT$660.92 Million
≈ $20.82 Million
+17.70pp
2016-12-31 2.19% NT$13.06 Million
≈ $411.43K
NT$597.49 Million
≈ $18.82 Million
--
pp = percentage points

About Sunmax Biotechnology Co Ltd

TWO:4728 Taiwan Biotechnology
Market Cap
$650.32 Million
NT$20.64 Billion TWD
Market Cap Rank
#10372 Global
#330 in Taiwan
Share Price
NT$379.00
Change (1 day)
-1.43%
52-Week Range
NT$373.00 - NT$409.00
All Time High
NT$494.50
About

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.